

8 October 2014

Notes:

- Target media: Selection national newspapers
- Key message(s): Cipla Medpro collaboration

MEDIA RELEASE

Cipla Medpro announces collaboration with world's largest generic pharmaceutical company

8 October 2014: Medpro Pharmaceutica (Pty) Ltd - a subsidiary company of Cipla Medpro, the third largest pharmaceutical company in South Africa, today announced that it has entered into a collaboration with Teva Pharmaceuticals (Pty) Ltd, an affiliate of Teva Pharmaceutical Industries Ltd (Teva) - the largest generic pharmaceutical manufacturer in the world with a presence in about 60 countries and approximately 45,000 dedicated employees worldwide. The collaboration is restricted to the territory of South Africa.

The collaboration is a sales and distribution arrangement whereby Cipla Medpro will exclusively market Teva's broad pharmaceutical product portfolio in South Africa.

"This collaboration is highly complementary and aligns strongly with our philosophy of providing South Africans with access to a broader range of affordable medicines," says **Paul Miller, Chief Executive Officer of Cipla Medpro.**

The collaboration with Teva in South Africa will focus on the following therapeutic areas: oncology, central nervous system, women's health, cardiovascular, ophthalmology and other specialty products.

"Cipla believes that the collaboration with Teva reaffirms its commitment to advancing healthcare for all South Africans," concludes **Subhanu Saxena, Managing Director and Global Chief Executive Officer of Cipla Limited.**

The collaboration is subject to approval by the Competition Commission of South Africa.

-ends-

About Cipla Medpro

Cipla Medpro - the third largest pharmaceutical company in South Africa - is a leading provider of affordable medicines to the public and private sectors. Cipla Medpro manufactures world class pharmaceuticals at cost-effective prices, making quality medicines affordable, and advancing healthcare for all South Africans.

About Cipla

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Our portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla's turnover in FY 2013-14 was 1.7 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems and has given India and the world many 'firsts' for instance Triomune. In a tightly regulated environment, the company's manufacturing facilities have approvals from all the main regulators including US FDA, UK MHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.